Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC

Next Previous
X
Search
Trial Profile

A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IO102 IO103 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Oropharyngeal cancer; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-D38
  • Sponsors IO Biotech

    • Most Recent Events

    • 25 Jul 2024 According to an IO Biotech media release, data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort from this study has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024 and will be presented at the Congress, which takes place in Barcelona from September 13-17, 2024.
    • 23 Jul 2024 Status changed from recruiting to active, no longer recruiting.
    • 14 May 2024 According to an IO Biotech media release, the company plans to submit abstracts with updates from this study to medical meetings in the fall of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top